The global stem cell patent landscape: implications for efficient technology transfer and commercial development

Characteristics of the complex and growing stem cell patent landscape indicate strategies by which public sector research institutions could improve the efficiency of intellectual property agreements and technology transfers in stem cells.

[1]  Leonard Berkowitz,et al.  Innovation and Its Discontents: How Our Broken Patent System Is Endangering Innovation and Progress and What to Do about It , 2005 .

[2]  Robert P. Merges,et al.  Contracting into Liability Rules: Intellectual Property Rights and Collective Rights Organizations , 1996 .

[3]  L. Giebel,et al.  Stem cells—a hard sell to investors , 2005, Nature Biotechnology.

[4]  A. Jaffe,et al.  Innovation policy and the economy , 2001 .

[5]  S. Filip,et al.  Issues in stem cell plasticity , 2004, Journal of cellular and molecular medicine.

[6]  V. Brower.  Human ES cells: Can you build a business around them? , 1999, Nature Biotechnology.

[7]  T. Winslow.  Regenerative Medicine 2006 , 2006 .

[8]  Christopher Thomas Scott,et al.  The paths around stem cell intellectual property , 2006, Nature Biotechnology.

[9]  Rudolf Jaenisch,et al.  Nuclear reprogramming and pluripotency , 2006, Nature.

[10]  D. Zilberman,et al.  An intellectual property clearinghouse for agricultural biotechnology , 2001, Nature Biotechnology.

[11]  J. Loring,et al.  Intellectual Property and Human Embryonic Stem Cell Research , 2006, Science.

[12]  Karen A. Holbrook,et al.  Public Sector Collaboration for Agricultural IP Management , 2003, Science.

[13]  S. Rabin.  The gatekeepers of hES cell products , 2005, Nature Biotechnology.

[14]  D. Zilberman,et al.  The public–private structure of intellectual property ownership in agricultural biotechnology , 2003, Nature Biotechnology.

[15]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.